Free Trial

Sutro Biopharma (STRO) Competitors

Sutro Biopharma logo
$0.76 -0.01 (-0.77%)
Closing price 04:00 PM Eastern
Extended Trading
$0.77 +0.01 (+1.18%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

STRO vs. CADL, ACB, IMMP, CRDF, FENC, SLRN, MNPR, PRQR, NBTX, and TVGN

Should you be buying Sutro Biopharma stock or one of its competitors? The main competitors of Sutro Biopharma include Candel Therapeutics (CADL), Aurora Cannabis (ACB), Prima BioMed (IMMP), Cardiff Oncology (CRDF), Adherex Technologies (FENC), Acelyrin (SLRN), Monopar Therapeutics (MNPR), ProQR Therapeutics (PRQR), Nanobiotix (NBTX), and Semper Paratus Acquisition (TVGN). These companies are all part of the "pharmaceutical products" industry.

Sutro Biopharma vs. Its Competitors

Candel Therapeutics (NASDAQ:CADL) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

Candel Therapeutics has a beta of -0.91, meaning that its share price is 191% less volatile than the S&P 500. Comparatively, Sutro Biopharma has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500.

In the previous week, Candel Therapeutics had 7 more articles in the media than Sutro Biopharma. MarketBeat recorded 7 mentions for Candel Therapeutics and 0 mentions for Sutro Biopharma. Candel Therapeutics' average media sentiment score of 1.16 beat Sutro Biopharma's score of 0.96 indicating that Candel Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Candel Therapeutics Positive
Sutro Biopharma Positive

13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are owned by institutional investors. 16.6% of Candel Therapeutics shares are owned by insiders. Comparatively, 3.6% of Sutro Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Candel Therapeutics presently has a consensus price target of $22.00, suggesting a potential upside of 226.41%. Sutro Biopharma has a consensus price target of $6.11, suggesting a potential upside of 704.51%. Given Sutro Biopharma's higher possible upside, analysts plainly believe Sutro Biopharma is more favorable than Candel Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Candel Therapeutics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20
Sutro Biopharma
1 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.25

Candel Therapeutics has higher earnings, but lower revenue than Sutro Biopharma. Candel Therapeutics is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Candel Therapeutics$120K2,813.95-$55.18M-$1.34-5.03
Sutro Biopharma$62.04M1.03-$227.46M-$2.98-0.26

Candel Therapeutics has a net margin of 0.00% compared to Sutro Biopharma's net margin of -373.66%. Candel Therapeutics' return on equity of -136.74% beat Sutro Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Candel TherapeuticsN/A -136.74% -63.13%
Sutro Biopharma -373.66%-347.60%-59.46%

Summary

Candel Therapeutics beats Sutro Biopharma on 11 of the 17 factors compared between the two stocks.

Get Sutro Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

STRO vs. The Competition

MetricSutro BiopharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$64.69M$2.96B$5.54B$9.41B
Dividend YieldN/A2.46%3.75%4.03%
P/E Ratio-0.268.2821.0120.09
Price / Sales1.03303.17433.8199.01
Price / CashN/A42.5936.1658.27
Price / Book1.417.678.125.65
Net Income-$227.46M-$55.28M$3.25B$257.91M
7 Day Performance-0.20%2.50%0.97%2.09%
1 Month Performance-4.26%11.70%7.36%11.13%
1 Year Performance-79.57%4.89%31.31%18.40%

Sutro Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
STRO
Sutro Biopharma
4.2057 of 5 stars
$0.76
-0.8%
$6.11
+704.5%
-81.1%$64.69M$62.04M-0.26240
CADL
Candel Therapeutics
2.518 of 5 stars
$4.99
-2.2%
$22.00
+340.9%
+5.3%$250.00M$120K-3.7260Positive News
ACB
Aurora Cannabis
0.3883 of 5 stars
$4.43
-2.4%
N/A-23.4%$249.01M$246.72M40.271,130
IMMP
Prima BioMed
1.5303 of 5 stars
$1.68
-2.3%
$7.00
+316.7%
-15.5%$245.35M$5.14M0.002,021Gap Up
CRDF
Cardiff Oncology
1.2919 of 5 stars
$3.65
-0.3%
$9.88
+170.5%
+75.2%$242.83M$680K-3.9720
FENC
Adherex Technologies
2.2886 of 5 stars
$8.47
-3.8%
$13.00
+53.5%
+31.6%$233.77M$47.54M-16.6110
SLRN
Acelyrin
N/A$2.27
flat
$9.60
+322.9%
N/A$229.17MN/A-0.92135
MNPR
Monopar Therapeutics
2.4252 of 5 stars
$37.20
+2.6%
$60.00
+61.3%
+1,231.0%$227.66MN/A-10.6910News Coverage
Insider Trade
PRQR
ProQR Therapeutics
2.6141 of 5 stars
$2.14
-1.8%
$8.00
+273.8%
+30.8%$225.15M$20.46M-6.11180
NBTX
Nanobiotix
2.6844 of 5 stars
$4.75
-2.5%
$8.00
+68.6%
-1.9%$223.68M$39.18M0.00100
TVGN
Semper Paratus Acquisition
4.1066 of 5 stars
$1.20
-3.2%
$10.00
+733.3%
+69.9%$220.67MN/A0.003News Coverage

Related Companies and Tools


This page (NASDAQ:STRO) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners